Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.52 |
| ▸ | RARA | P10276 | 3/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | RARG | P13631 | 5/20 | 0.47 |
| ▸ | RARB | P10826 | 4/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516470 | 0.88 | RXRA (0.51) | RXRARARAGRIK1GRIA1GRIA2 | |
| SCHEMBL4507665 | 0.86 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL4501828 | 0.81 | MAPK14 (0.64) | MAPK14 | |
| SCHEMBL27599821 | 0.80 | TDP2 (0.48) | RXRARARARARGRARBTDP2 | |
| SCHEMBL3058616 | 0.79 | MAPK14 (0.51) | MAPK14 | |
| SCHEMBL4504889 | 0.74 | MAPK14 (0.60) | MAPK14 | |
| SCHEMBL4503763 | 0.73 | HRH3 (0.48) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL4502525 | 0.73 | MAPK14 (0.53) | RARARARGRARBMAPK14DGAT1 | |
| SCHEMBL21517841 | 0.72 | GRIA1 (0.64) | RXRARARAGRIK1GRIA1GRIA2 | |
| SCHEMBL4503416 | 0.72 | MAPK14 (0.55) | RXRARARAMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPKAPK3 | RXRA 2573/4885RARA 3325/4885GRIK1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.